B Arach

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

James Hakim, Cissy Kityo, Anne Hoppé et al. · The Lancet Infectious Diseases · 2017 · 41 citations · Full text

Pharmacy, Infectious Disease Control, Pharmacotherapy +17

Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial

Abraham Siika, Leanne McCabe, Mutsa Bwakura‐Dangarembizi et al. · Clinical Infectious Diseases · 2018 · 35 citations · Full text

Public Health, Infectious Disease Control, Infectious Diseases +17

Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial

Jane Mallewa, Alexander J. Szubert, Peter Mugyenyi et al. · The Lancet HIV · 2018 · 32 citations · Full text

Agriculture, Nutrition, Nutritional Sciences +17

Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV

Felicity Fitzgerald, Édouard Lhomme, Kathryn Harris et al. · The Journal of Infectious Diseases · 2018 · 17 citations · Full text

Life Sciences, Immunology, Microbiology +10

Anthropometric Measurements and Lipid Profiles to Detect Early Lipodystrophy in Antiretroviral Therapy Experienced HIV-Infected Children in the Chapas-3 Trial

Victor Musiime, Adrian Cook, Joshua Kayiwa et al. · Antiviral Therapy · 2013 · 15 citations · Full text

Public Health, Child Health, Pediatrics +15